COR vs HSIC — Key Metrics
| Metric | COR (CENCORA INC) | HSIC (HENRY SCHEIN INC) |
|---|---|---|
| Price | 348.31 | 85.69 |
| Market Cap | 66.47 Billion | 9.47 Billion |
| P/E (TTM) | 25.76 | 23.29 |
| P/B (Quarterly) | 19.841 | 2.887 |
| P/S (TTM) | 0.2 | 0.69 |
| Net Profit Margin (TTM) | 0.8 | 3.1 |
| Gross Margin (TTM) | 4.0 | 31.6 |
| ROE (TTM) | 106.4 | 13.1 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Greatly Outperform
Recommendation Summary
Stock COR is projected to outperform the market, stock HSIC is projected to greatly outperform the market. Upfront Recommendation: HSIC.
Financial Metrics
| COR | Metrics | HSIC |
|---|---|---|
| $348.31 | Price | $85.69 |
| — | Market Capitalization | — |
| 25.76 | Price to Earnings Ratio | 23.29 |
| 0.2 | Price to Sales | 0.69 |
| 16.19 | Price to FCF Ratio | 18.94 |
| 5.03 | Price to Gross Profit | 2.18 |
| 1.2 | Price to Current Assets | 1.98 |
COR vs HSIC at a glance
Cencora INC (COR) and Henry Schein INC (HSIC) are both Medical Distribution companies in the Healthcare sector. COR is the larger, at $66.5 billion in market value against $9.5 billion for HSIC, about 7.0 times the size.
On trailing-twelve-month figures, COR trades at 25.8 times trailing earnings and HSIC at 23.3; net profit margins are 0.8% and 3.1%.
The Upfront Investment model currently rates COR Outperform and HSIC Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.